Excitement and investment in the microbiome and its near-term opportunities for the biopharma industry are rapidly increasing. As the microbiome is implicated in progressively more diseases, emerging studies have validated the concept of microbiome-based diagnostics and therapeutics. The accelerating pace of scientific and technologic advances makes it especially challenging for industry leaders to keep up with the latest developments, and understand their scientific and strategic implications. “The Microbiome: Emerging Opportunities for Biopharma” is a Harvard Medical School executive education program designed to address this gap.
Led by Ramnik Xavier, MD, PhD, and other renowned Harvard Medical School faculty and leaders in industry, participants will complete the program with a framework to guide their thinking about how to evaluate microbiome programs, identify emerging areas of opportunity and set strategic priorities for research, discovery and investment. For more information about The Microbiome program, visit https://hms.harvard.edu/microbiome.